Liraglutide and semaglutide are both GLP-1 receptor agonists — same target, same receptor, fundamentally different results. One is daily, the other weekly. One produces moderate weight loss, the other roughly doubles it. But choosing between them is not as simple as picking the stronger one.
This comparison is anchored to the STEP 8 trial — the only head-to-head RCT directly comparing these two molecules for weight management.
Side-by-side evidence
Outcomes where both peptides have published data. Each cell carries two grades: clinical evidence (human-RCT depth for this specific outcome) and community evidence (real-world adoption). How we grade evidence.
| Outcome | Liraglutide | Semaglutide |
|---|---|---|
| Body weight reduction | Clinical:Strong Community:Strong ~5-8% weight loss in SCALE trials at 3.0 mg daily over 56 weeks. | Clinical:Strong Community:Moderate ~14.9% weight loss in STEP 1 at 2.4 mg weekly over 68 weeks. |
| Glycemic control (HbA1c) | Clinical:Strong Community:Strong Solid HbA1c reductions (~1.0-1.2 points) across LEAD trials. | Clinical:Strong Community:Moderate Larger HbA1c reductions (~1.4-1.8 points) across SUSTAIN trials. |
| Cardiovascular outcomes | Clinical:Strong Community:Strong LEADER trial: 13% reduction in MACE in T2D with high CV risk. | Clinical:Strong Community:Moderate SUSTAIN-6: 26% reduction in MACE; SELECT trial confirmed CV benefit in non-diabetic obesity. |
| Dose convenience | Clinical:Strong Community:Strong Daily subcutaneous injection. | Clinical:Strong Community:Moderate Once-weekly subcutaneous injection (also available as oral tablet). |
Quick Comparison
| Feature | Liraglutide | Semaglutide |
|---|---|---|
| Dosing frequency | Once daily | Once weekly |
| Target dose (weight loss) | 3.0 mg/day | 2.4 mg/week |
| Titration period | 5 weeks | 16-20 weeks |
| Average weight loss | 6.4% (STEP 8) | 15.8% (STEP 8) |
| Half-life | ~13 hours | ~7 days |
| Structural homology to GLP-1 | 97% | 94% |
| CV outcomes trial | LEADER (positive) | SELECT (positive) |
| FDA approval (weight) | 2014 | 2021 |
Mechanism: Same Receptor, Different Pharmacology
Both liraglutide and semaglutide are GLP-1 receptor agonists that activate the same receptor. The pharmacological differences explain the efficacy gap.
Liraglutide uses a C16 fatty acid (palmitic acid) chain for albumin binding, achieving a 13-hour half-life. This requires daily injection and means plasma levels fluctuate throughout the day — higher after injection, lower before the next dose (Neumiller, 2011).
Semaglutide uses a C18 fatty acid chain with a linker that dramatically increases albumin binding affinity, plus an amino acid substitution at position 8 that prevents DPP-4 degradation. The result is a ~7-day half-life with stable plasma levels throughout the week (Muller et al., 2021).
The sustained receptor occupancy with semaglutide likely explains its superior weight loss — the hypothalamic GLP-1 receptors controlling appetite are activated more consistently, producing more sustained appetite suppression.
Weight Loss: Head-to-Head Data
The STEP 8 trial is the definitive comparison — the only head-to-head RCT in adults with overweight or obesity without diabetes.
338 participants were randomized to semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily, or placebo for 68 weeks. Results (Rubino et al., 2022):
| Outcome | Semaglutide 2.4mg | Liraglutide 3.0mg | Difference |
|---|---|---|---|
| Mean weight loss | -15.8% | -6.4% | 9.4 pp (P<.001) |
| >=10% weight loss | 70.9% | 25.6% | |
| >=15% weight loss | 55.6% | 12.0% | |
| >=20% weight loss | 38.5% | 6.0% |
Semaglutide produced roughly 2.5 times the weight loss of liraglutide, with the gap widening at higher thresholds. More than half of semaglutide users lost 15%+ body weight, while only 12% of liraglutide users achieved the same.
This is not a close competition for weight loss. Semaglutide wins decisively.
Cardiovascular Outcomes
Both molecules have demonstrated cardiovascular benefit in dedicated outcomes trials, but the trial populations differ.
LEADER (liraglutide): 9,340 patients with T2D and high CV risk. Median follow-up 3.8 years. Results: 13% reduction in MACE, 22% reduction in CV death (Marso et al., 2016).
SELECT (semaglutide): 17,604 patients with established CV disease and overweight/obesity (without diabetes requirement). 20% reduction in MACE. SELECT was a larger trial with a broader population, making direct comparison difficult.
Both demonstrate cardiovascular protection. LEADER has the advantage of longer follow-up data. SELECT has the advantage of a larger sample and a population not limited to T2D.
Side Effects
The GI side effect profiles are remarkably similar in type — the difference is in tolerability and discontinuation rates.
STEP 8 Head-to-Head Safety Data
| Side Effect | Semaglutide | Liraglutide |
|---|---|---|
| Any GI adverse event | 84.1% | 82.7% |
| Nausea | ~44% | ~39% |
| Diarrhea | ~22% | ~21% |
| Constipation | ~20% | ~19% |
| Vomiting | ~19% | ~16% |
| Treatment discontinuation | 13.5% | 27.6% |
The standout finding: despite similar GI event rates, twice as many liraglutide users discontinued treatment. This likely reflects that daily injection burden compounds the tolerability challenge. When you feel nauseated every day and also have to inject every day, compliance drops. Semaglutide's weekly dosing provides a psychological buffer.
Both share the same serious but rare risks: pancreatitis (<0.5%), gallbladder events (related to rapid weight loss), and the class-wide thyroid C-cell tumor boxed warning (rodent data, unconfirmed in humans).
Ready to buy? Compare verified vendors on our best liraglutide sources page, or browse all coupon codes for up to 50% off.
